ClinicalTrials.gg
Status unknownNCT00005663Updated Jun 24, 2005

A Study of Valacyclovir as Treatment for Genital Herpes Simplex Virus in HIV-Infected Patients

A Phase 3 interventional study of Valacyclovir hydrochloride in Herpes Simplex, HIV Infections and Herpes Genitalis, sponsored by Glaxo Wellcome. Status unknown at 24 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.

Primary conditionHerpes GenitalisRegistry: Herpes SimplexReclassifiedWhy we changed it
Registry
Herpes Simplex — the first condition term the registry derived for this study.
ClinicalTrials.gg
Herpes Genitalis
Why
  1. The study's listed conditions name Herpes Genitalis, a narrower term within Herpes Simplex.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Glaxo Wellcome (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2001), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing valacyclovir in Herpes Genitalis — none open to participants now, none under way, none of them phase 3. Valacyclovir · Herpes Genitalis.

Started
1999
the only one that year
Phase 3
2 of 14
none open now
Registered
4th of 14
by date
Lead sponsor
4 of 14
Glaxo Wellcome

Among the 14 studies testing valacyclovir in Herpes Genitalis, this one is the only one that started in 1999, is one of 2 in phase 3, and was the 4th registered.

Herpes Genitalis

70 studies on the registry are indexed under Herpes Genitalis; 3 are open to participants now.

Browse Herpes Genitalis studies →

Open to participants now

None of the 14 studies testing valacyclovir in Herpes Genitalis is open now. The open studies under Herpes Genitalis, anywhere →

About valacyclovir

Valacyclovir: first FDA approval 1995 (VALTREX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1 Herpes Genitalis study recruiting now, none set no upper age limit and 1 stops at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing valacyclovir in Herpes Genitalis as a file.
02

Study summary

The purpose of this study is to see if valacyclovir (Valtrex) is a safe and effective treatment for ano-genital HSV infections (herpes simplex virus infections of the anus and external genitals) in HIV-infected patients.

Read the detailed description

Patients are randomized in a 2:1 ratio to receive either Valtrex or placebo, twice daily, for up to 6 months. Patients come to the clinic for routine monthly assessments for 6 months, and return to the clinic for evaluation within 24 hours of the first signs or symptoms of an ano-genital HSV recurrence. Once the clinician confirms the presence of at least the macular/papular lesion stage, double-blind suppressive therapy is discontinued and open-label treatment with a higher dose of Valtrex twice daily for 5 days is initiated. For the first recurrence, patients are instructed to return to the clinic for further clinical assessments on Day 5 of the recurrence. Patients who have not healed by Day 5 may be offered an additional five days of open-label treatment, as deemed appropriate by the clinical investigator. If an additional 5-day course of open-label treatment medication is dispensed, the patient returns to the clinic on Day 10 for evaluation. Patients who have not healed by Day 10 are managed as deemed appropriate by the investigator. Once treatment of the first ano-genital HSV recurrence is complete and the patient is healed, patients are switched to open-label suppressive therapy with Valtrex for the remainder of the study period (up to a maximum of 6 months). The total duration of the study for all patients is 6 months.

03

Conditions studied

  • Herpes Simplex
  • HIV Infections
  • Herpes Genitalis

Browse trials for

Keywords

  • Herpes Simplex
  • Antiviral Agents
  • Anus Diseases
  • Herpes Genitalis
  • Recurrence
  • valacyclovir
04

In context

Herpes Genitalis Reclassified

70 studies on the registry are indexed under Herpes Genitalis; 3 are open to participants now.

Browse Herpes Genitalis studies →

Lead sponsor

Glaxo Wellcome is the lead sponsor of 72 studies on the registry; none are open to participants now.

First submitted before Glaxo Wellcome became part of GlaxoSmithKline.

Compared within Herpes Genitalis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Herpes Simplex. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients may be eligible for this study if they:

  • Are at least 18 years old.
  • Are -positive.
  • Have herpes simplex virus (HSV) 2.
  • Have received combination anti-HIV therapy for at least 2 months before entering the study.
  • Have had 4 or more recurrences of ano-genital HSV (herpes infection of the anus and genitals) in the last 12 months. (If patient is taking medication to control HSV, then he/she must have had 4 or more recurrences of ano-genital HSV per year before beginning regular anti-HSV therapy, which is defined as therapy of 12 or more weeks.)
  • Agree to use effective methods of from 2 weeks before taking study drug, throughout the study, and for 4 weeks after completing the study. (A female may be eligible if not able to have children.)

Exclusion criteria

Exclusion Criteria

Patients will not be eligible for this study if they:

  • Have blood vessel disease.
  • Are sensitive to acyclovir, Valtrex, famciclovir, or ganciclovir.
  • Are unable to take medications by mouth.
  • Have non-healed sores on the anus or genitals at beginning of study.
  • Are using anti-herpes drugs. To be eligible for enrollment, patients currently using anti-herpes drugs must stop treatment with these drugs at the beginning of the study; however, therapy may be started again if the investigator finds it necessary.
  • Are using interferon. Patients receiving interferon must stop interferon before beginning the study.
  • Have kidney or liver problems.
  • Are pregnant or breast-feeding.
  • Have a type of HSV that is resistant to acyclovir, Valtrex, famciclovir, or ganciclovir.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Masking
Double
07

Study locations

24 sites
  • East Bay AIDS Ctr
    Berkeley, California 94705, United States
  • Pacific Oaks Research
    Beverly Hills, California 90211, United States
  • Kraus Med Partners
    Los Angeles, California 90036, United States
  • ViRx Inc
    San Francisco, California 94109, United States
  • IDC Research Initiative
    Altamonte Springs, Florida 32701, United States
  • Healthnet Institute
    Fort Lauderdale, Florida 33316, United States
  • Univ of Miami School of Medicine
    Miami, Florida 331361013, United States
  • Treasure Coast Infectious Disease Consultants
    Vero Beach, Florida 32960, United States
  • Palm Beach Research Ctr
    West Palm Beach, Florida 33409, United States
  • Indiana Univ School of Medicine / Dept of Infect Dis
    Indianapolis, Indiana 46202, United States
  • Univ of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Advanced Biomedical Research Inc
    Hackensack, New Jersey 07601, United States
  • Nalle Clinic / Clinical Research Dept
    Charlotte, North Carolina 28207, United States
  • Wake County Dept of Health
    Raleigh, North Carolina 27610, United States
  • Westover Heights Clinic
    Portland, Oregon 97210, United States
  • Philadelphia FIGHT
    Philadelphia, Pennsylvania 19107, United States
  • Dr Alvan Fisher
    Providence, Rhode Island 02907, United States
  • Baylor College of Medicine / Dept of Medicine
    Houston, Texas 770303498, United States
  • Richmond AIDS Consortium
    Richmond, Virginia 23219, United States
  • Univ of Washington Virology Research Clinic
    Seattle, Washington 98122, United States
  • Dr Barbara Romanowski
    Edmonton, Alberta, Canada
  • Sunnybrook Health Science Ctr
    Toronto, Ontario, Canada
  • Clinique Medicale L'Actuele
    Montreal, Quebec, Canada
  • Centre De Recherche En Infectiologie
    Ste Foy, Quebec, Canada
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00005663
Lead sponsor
Glaxo Wellcome
First posted
Aug 31, 2001
Start date
Jun 1999
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2001. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valacyclovir

Start the discussion